ID NOW COVID-19 Testing Questions Answered

ID NOW COVID-19 TESTING QUESTIONS

LAST UPDATED: MAY 04 2020

The ID NOW COVID-19 test is a rapid, molecular point-of-care test that detects COVID-19 in 13 minutes or less. It is used on our ID NOW platform. Abbott received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the ID NOW COVID-19 test in March 2020. ID NOW is an FDA approved CLIA-waived instrument, which means that the technology can be used in settings outside the traditional hospital setting. Healthcare professionals using ID NOW should be trained on how to use the instrument. Learn more.

ID NOW is a lightweight and portable instrument (just 6.6 pounds and the size of a toaster) that allows testing to occur near the patient to get rapid results – including in physicians' offices, urgent care settings, and hospital emergency departments.

This article helps explain how the ID NOW molecular point-of-care test for COVID-19 works. Learn more.

Results may be delivered in 13 minutes or less.

Our ID NOW molecular point-of-care test met all testing criteria in the FDA's emergency use authorization (EUA) and we’re continuing to collect more clinical data in the field. The ID NOW instrument uses molecular technology and molecular tests in general are valued for their high level of accuracy in similar settings such as flu testing. Learn more.

The direct swab method is the best way to ensure the test performs as expected.

To optimize results, do not use viral transport media (VTM), which could reduce the sensitivity of the test through dilution. Learn more.

The ID NOW testing process is safe and does not endanger operators as long as the collection and processing of samples follow the universal precaution techniques outlined by CDC guidelines. Learn more.

ID NOW has been in use since 2014 to detect flu, strep, and RSV. Clinicians and lab professionals have been using the same ID NOW instrument, collection swabs, and consumables (such as the sample receiver and transfer cartridge) to safely test respiratory viruses during this time.

We are producing 50,000 COVID-19 tests a day for our ID NOW system. Were continuing to ramp up our ID NOW manufacturing and plan to increase capacity to 2 million tests a month by June and are working to expand beyond that. Check out our most recent progress update here.

Currently, the ID NOW COVID-19 test is available only in the U.S. under emergency use authorization (EUA) as this is where the majority of our ID NOW instruments are in use today.

If you are an individual, please reach out to your healthcare provider. If you're with a hospital, lab, or healthcare provider, you can contact us for questions about ID NOW here.

Learn more about all of Abbott's testing solutions to tackle the coronavirus.

Press release announcing launch of the ID NOW COVID-19 test here.

This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

INVESTORS

NEWSROOM

RESPONSIBILITY

SUBSCRIBE

CONSUMERS

HEALTHCARE PROFESSIONALS

CAREERS

ABOUT ABBOTT

CAREERS

INVESTORS

NEWSROOM

Responsibility

Partners

Contact

SITE MAP

POLICIES

privacy policy

Terms & Conditions